Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support CERo's clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML.
AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells ("CER-T") therapies, which involve engineering a patient's own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it's critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product – underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM.
LabPMM's CAP/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo's drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial.
Kristen Pierce, Ph.D., CERo Chief Development Officer, commented, "Invivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response."
This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML2. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe's commitment to driving innovation and standardization across the oncology treatment landscape – now helping bring immunotherapies to patients faster.
For more information about LabPMM's flow cytometry and molecular testing services, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
About Invivoscribe Inc.
Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.
1 https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/introduction 2 https://www.cero.bio/press-release?storyId=7477275225065985
View source version on businesswire.com: https://www.businesswire.com/news/home/20250707133010/en/
Contacts
inquiry@invivoscribe.com
Connectez-vous pour accéder à votre portefeuille
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Soluna Holdings Stock Rises on Data Center Expansion With 'Top-Tier Bitcoin Miner'
Soluna Holdings shares rose in early trading Tuesday after the maker of green data centers announced an expansion of its Texas site with a company it called a 'top-tier Bitcoin miner." 'With this deal, Project Dorothy 2 is now fully marketed and contracted,' Soluna said. Soluna shares have fallen almost 70% this Holdings (SLNH) shares rose in early trading Tuesday after the maker of green data centers announced an expansion of its Texas site with a company it called a 'top-tier Bitcoin miner.' 'With this deal, Project Dorothy 2 is now fully marketed and contracted,' Soluna said. The data center developer said it has expanded its flagship project site Project Dorothy 2 by 30 megawatts in its third buildout with this customer, which it didn't name. 'It's a major milestone in our growth pipeline, bringing 100% of our active facilities to full capacity,' Soluna CEO John Belizaire said. Soluna shares rose 4.6% in early trading Tuesday. The company's shares have fallen almost 70% so far this year. Read the original article on Investopedia
Yahoo
27 minutes ago
- Yahoo
World-First Fusion Demonstration Machine Designed and Optimized Using COMSOL Multiphysics®
General Fusion uses multiphysics simulation to analyze the internal behavior of a fusion demonstration machine and predict its performance BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- COMSOL, a global leader in modeling and simulation software, today announced that engineers at General Fusion have used the COMSOL Multiphysics® software to design and optimize a large-scale fusion demonstration machine called Lawson Machine 26 (LM26), which it has successfully begun operating. LM26 will be used to de-risk General Fusion's eventual commercial Magnetized Target Fusion (MTF) machine, which works by compressing a magnetized plasma with a liquid metal liner to achieve the high temperatures and pressures needed for fusion. With MTF technology, General Fusion aims to bring fusion power to the commercial power grid by the early to mid 2030s. MTF power plants have the potential to produce significant amounts of energy with comparatively inexpensive technology and without releasing carbon emissions. General Fusion's partnership with Veryst Engineering, a COMSOL Certified Consultant specializing in highly nonlinear simulation and material modeling, was essential in the development of LM26. Sean Teller, a principal engineer at Veryst, worked alongside Jean-Sebastien Dick, an engineering analysis manager at General Fusion, to develop material models that enabled the team to accurately simulate the response of the machine's lithium liner. This information was critical for accurate predictive modeling of the LM26 liner trajectories, which enabled General Fusion to create and assemble LM26. As Teller explained, "We used COMSOL Multiphysics simulation with integrated experimental plans and validation to enable the team at General Fusion to quickly iterate on designs of LM26. The predictive models are critical for achieving fusion conditions on the road to viable and abundant clean fusion power."The LM26 geometry. Different LM26 designs were able to be analyzed simultaneously in the COMSOL® software. During the validation campaign of the models, 40 lithium liners were compressed electromagnetically. The team conducted physical experiments using a small-scale prototype of the compression system. Modeling and simulation enabled General Fusion to adjust the impedance of the power supply, see how design alterations would impact the performance, and maximize the compression fully assembled LM26. "The framework of COMSOL has allowed us to incrementally build in complexity, build confidence in our design intentions, and avoid having to reiterate the design phases," Dick said. "We have not had to change any major parts of these experiments. They were always behaving as intended." General Fusion achieved a major milestone with LM26 in April, successfully compressing a large-scale magnetized plasma with lithium. The full, integrated system and diagnostics operated as designed, and early review of data indicates positive results. The development of LM26 is discussed in further detail in the COMSOL User Story Gallery: About COMSOL COMSOL is a global provider of simulation software for product design and research to technical enterprises, research labs, and universities. Its COMSOL Multiphysics® product is an integrated software environment for creating physics-based models and simulation apps. A particular strength is its ability to account for coupled or multiphysics phenomena. Add-on products expand the simulation platform for electromagnetics, structural, acoustics, fluid flow, heat transfer, and chemical applications. Interfacing tools enable the integration of COMSOL Multiphysics simulations with all major technical computing and CAD tools on the CAE market. Simulation experts rely on COMSOL Compiler™ and COMSOL Server™ to distribute apps to their design teams, manufacturing departments, test laboratories, and customers throughout the world. Founded in 1986, COMSOL has 16 offices worldwide and extends its reach with a network of distributors. COMSOL, COMSOL Multiphysics, COMSOL Compiler, and COMSOL Server are either registered trademarks or trademarks of COMSOL AB. Contact:Mike Nourie(781) Photos accompanying this announcement are available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
DHI Group Gains Analyst Support Amid Cost-Cutting Restructuring Strategy
DHI Group, Inc. (NYSE:DHX) is one of the . Following the announcement of a significant workforce restructuring, the company got its Buy rating reaffirmed by analysts. A prestigious team of executive recruiters networking at a professional event. The New York-based company DHI Group, Inc. (NYSE:DHX) is a provider of AI-powered career marketplaces targeting technology and security-cleared professionals. Founded in 1990, the company operates through brands like Dice and ClearanceJobs and connects technologists with job opportunities and serves candidates with active U.S. security clearances. On June 23, 2025, the company announced a significant organizational restructuring. Reducing the workforce by 25% approximately, the company aimed at lowering the operating costs for its Dice brand. The company believed that the restructuring would lead to annual savings between $14 million and $16 million. It anticipates the completion of the restructuring process by July 2025. On June 24, 2025, Lake Street maintained its Buy rating for the stock, with a price target of $3.50, reinforcing its confidence in DHI Group, Inc. (NYSE:DHX)'s progress. With a one-year consensus median price target of $4.25 from 3 analysts as per CNN, the stock is available at $2.97 as of June 30, 2025, for investors seeking to modify their portfolio with the best penny stocks in the market. While we acknowledge the potential of DHX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Low Risk Dividend Paying Stocks for June 2025 and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
